Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBT Margin: 2010-2021

Historic EBT Margin for Neurocrine Biosciences (NBIX) over the last 9 years, with Sep 2021 value amounting to 10.30%.

  • Neurocrine Biosciences' EBT Margin rose 3239.00% to 10.30% in Q3 2021 from the same period last year, while for Sep 2021 it was 5.43%, marking a year-over-year decrease of 451.00%. This contributed to the annual value of 5.91% for FY2019, which is 106.00% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported EBT Margin of 10.30% as of Q3 2021, which was down 48.23% from 19.90% recorded in Q2 2021.
  • Neurocrine Biosciences' EBT Margin's 5-year high stood at 33.45% during Q3 2018, with a 5-year trough of -960.76% in Q2 2017.
  • Its 3-year average for EBT Margin is 5.99%, with a median of 16.12% in 2020.
  • In the last 5 years, Neurocrine Biosciences' EBT Margin skyrocketed by 95,466bps in 2018 and then crashed by 4,838bps in 2020.
  • Neurocrine Biosciences' EBT Margin (Quarterly) stood at 7.29% in 2017, then surged by 701bps to 14.30% in 2018, then surged by 153bps to 15.83% in 2019, then plummeted by 4,838bps to -22.09% in 2020, then spiked by 3,239bps to 10.30% in 2021.
  • Its EBT Margin stands at 10.30% for Q3 2021, versus 19.90% for Q2 2021 and 11.50% for Q1 2021.